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Abstract
Diisocyanates (dNCOs) used in industrial applications are well known low molecular weight 
allergens. Occupational exposure is associated with adverse health outcomes including allergic 
sensitization and occupational asthma. In this study, we report the production and initial 
characterization of a dNCO-hapten specific murine IgM monoclonal antibody (mAb). Female 
BALB/c mice were immunized intraperitoneally with 25 µg of 4,4′-methylene diphenyl 
diisocyanate (MDI)-keyhole limpet hemocyanin. Following six biweekly booster immunizations, 
splenocytes were recovered and fused to Sp2/0-Ag14 murine myeloma cell line for hybridoma 
production. Hybridomas were then screened in a solid-phase indirect enzyme-linked 
immunosorbent assay (ELISA) against 40:1 4,4′-MDI– human serum albumin (HSA). mAb 
reactivity to dNCO-HSA conjugates and dNCO-HSA spiked human serum were characterized 
using a sandwich ELISA. One hybridoma produced a multimeric IgM mAb (15D4) that reacted 
with 4,4′-MDI-HSA. Sandwich ELISA analysis demonstrated comparable reactivity with other 
occupationally relevant dNCO-HSA adducts, including 2,4-toluene diisocyanate (TDI)-HSA, 2,6-
TDI-HSA, and 1,6-hexamethylene diisocyanate (HDI)-HSA, but not other electrophilic chemical 
HSA conjugates. The limit of quantification (LOQ) of 4,4′-MDI-HSA, 2,4-TDI-HSA, 2,6-TDI-
HSA, and 1,6-HDI-HSA sandwich ELISAs were 567.2, 172.7, 184.2, and 403.5 ng/mL (8.67, 
2.60, 2.77, and 6.07 pmol/mL), respectively. In contrast, experiments using dNCO-supplemented 
human sera showed an increase in the detectable limit of the assay. A mAb has been produced that 
has potential utility for detecting mixed diisocyanate exposures in occupational environments. The 
mAb may have additional utility in the standardization of specific IgE detection immunoassays as 
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well as chromatographic-mass spectrometric methods to enrich dNCO adducted HSA in the 
plasma of occupationally exposed workers.
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INTRODUCTION
Diisocyanates (dNCO) are commonly utilized chemicals in the manufacturing sector due to 
their reactivity with free hydroxyl groups to produce polyurethane polymers. Examples of 
commercially available products include flexible or rigid foams, elastomers, surface 
coatings, adhesives, sealants, varnishes, and paints.(1) The two most common dNCOs used 
in industrial applications include methylene diphenyl diisocyanate (MDI) and toluene 
diisocyanate (TDI).(1) Hexamethylene diisocyanate (HDI)- and isophorone diisocyanate 
(IPDI)-based oligomers are also utilized in the automotive industry and autobody repair. In 
2010, the annual consumption of dNCO in the United States was 1.9 billion pounds(2) and 
the National Institute of Occupational Safety and Health (NIOSH) estimates more than 
250,000 workers are occupationally exposed to dNCOs.(3)
Diisocyanates are potent sensitizers and are the most commonly reported cause of 
occupational asthma (OA) in North America.(4,5) Occupational exposure to dNCOs may 
result in other adverse health outcomes including immune mediated hypersensitivity 
pneumonitis (HP),(6) reactive airways dysfunction syndrome,(5) and allergic contact 
dermatitis, as well as irritation of the skin and mucous membranes.(7–11) Currently, NIOSH 
recognizes worker exposure to liquid, vapor, or aerosol dNCOs as both a respiratory and 
dermal occupational hazard and the recommended permissible exposure limit (PEL) should 
not exceed 0.005 part per million for each dNCO.(7)
In spite of the documented health hazards, the allergenic forms of dNCO hapten-protein 
conjugated products that are produced following occupational exposure remain less clear. 
These limitations have confounded serodiagnosis and exposure assessment using 
immunological approaches. dNCOs are electrophiles that react with amines and thiols on 
proteins.(12) Potential endogenous dNCO adducts have been reported and include 
glutathione, tubulin, actin, keratin, hemoglobin, and human serum albumin (HSA).(4,13) 
Recently, binding sites of TDI have been shown to react with the N-terminal amine of HSA, 
the ε-amino group (ε-NH2) of lysine, and 37 other binding sites on HSA using a high TDI-
HSA conjugation ratio (40:1).(12) Although less reactive, similar binding sites have been 
reported for MDI.(14) Given the abundance of HSA in human serum, these data indicate that 
dNCO-HSA reaction products may serve as potential serological biomarkers of occupational 
exposure.
Due to the hazards associated with occupational exposure to dNCOs, there has been great 
interest in the development of sensitive biomonitoring methodologies for evaluating worker 
exposure. To date, the availability of antibodies for the serological detection of dNCO-
protein adducts has been limited. Polyclonal antibodies (pAbs) against HDI-HSA conjugates 
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have been reported for biomonitoring HDI occupational exposures.(15) Ruwona et al. have 
developed murine IgM and IgG mAbs with unique specificity for TDI-HSA and other 
protein adducts.(16,17) More recently, six IgG1 mAbs with specific reactivity for MDI-
protein adducts have been reported by Wisnewski and Liu.(18) Although these antibodies 
have provided potential new tools for the isolation and identification of TDI and MDI target 
proteins, to our knowledge there are no mAbs that react with either HDI or a combination of 
other occupationally relevant dNCOs. In this study, we report the production and initial 




4,4′-methylene diphenyl diisocyanate (MDI, CAS 101-68-8, Sigma Aldrich, St. Louis, Mo.) 
was bound to keyhole limpet hemocyanin (KLH). Conjugates used for murine 
immunizations were prepared in 0.01 M phosphate buffered saline (PBS, pH 7.4) at a KLH 
(Thermo Fisher Scientific, Rochester, N.Y.) concentration of 0.5 mg/mL. MDI was added to 
the KLH solution at a molar ratio of 40 4,4′-MDI:1 KLH. Stock solutions (0.03 M) were 
prepared by dissolving 4,4′-MDI in dry acetone immediately prior to conjugation. The 4,4′-
MDI solution (50 µL) was added to 5 mL KLH solution drop wise while vortexing. The 
conjugate was vortexed for 1 h at room temperature (RT). Conjugates were dialyzed using a 
12,144MWCOdialysis membrane (Sigma Aldrich) to remove residual polymerized MDI or 
methylene dianiline (MDA), an amine generated after MDI hydrolysis. 4,4′-MDI-KLH 
antigen was stored at 4°C throughout the duration of experiments.
Vertebrate Animals
Mice were acclimated for approximately one week prior to 4,4′-MDI-KLH immunizations. 
The mice were housed in HEPA-filtered ventilated polycarbonate cages on autoclaved 
hardwood chip bedding. The temperature in the animal facility was maintained between 68 
and 72°F and the relative humidity between 36 and 57%. The light/dark cycle was 
maintained on 12-hour intervals. Mice were provided NIH-31 modified 6% irradiated rodent 
diet (Harlan Laboratories, Madison, Wisc.) and autoclaved tap water ad libitum. Sentinel 
mice housed in the animal quarters were free of viral pathogens, parasites, mycoplasmas, 
Helicobacter spp., and cilia-associated respiratory Bacillus spp. The NIOSH animal facility 
is an environmentally controlled barrier facility that is fully accredited by the Association 
for the Assessment and Accreditations of Laboratory Animal Care International. All animal 
procedures were performed under a NIOSH Animal Care and Use Committee-approved 
protocol 11-PS-M-006.
Immunization of Female BALB/c Mice
Five female BALB/c mice (The Jackson Laboratory, Bar Harbor, Me.) aged 5–7weeks were 
immunized intraperitoneally (IP) with a 50:50 (v/v) emulsion of 25 µg 4,4′ -MDI-KLH and 
TiterMax Gold Adjuvant (TiterMAX USA, Norcross, Ga.). Five subsequent booster IP 
immunizations containing 25 µg 4,4′-MDI-KLH in sterile PBS were administered at 
biweekly intervals. The final boost was administered 3 days before the monoclonal antibody 
Lemons et al. Page 3













(mAb) fusion. Approximately, 100µLof blood was collected from the tail of each mouse 7 
days prior to the first immunization (pre-bleed) and 7 days after each subsequent booster 
immunization (post-bleed) to monitor the development of immune responses.
MDI-antisera Screening ELISA
Pre- and post-immunization mouse sera were screened using an ELISA to determine anti-
MDI-HSA titers. Briefly, 96-well Nunc Immuno MaxiSorp microplates (Thermo Fisher 
Scientific) were coated with 5 µg/mL 40:1 MDI-HSA in carbonate coating buffer (CCB, 60 
mM sodium carbonate, 140 mM sodium bicarbonate, pH 9.6) and incubated at RT 
overnight. Wells were washed three times with PBS containing 0.05% Tween-20 (PBST) 
and blocked for 1 h at RT with 200 µL PBST containing 3% non-fat dry skim milk powder 
(SMPBST). Murine immunoglobulin G (IgG) titers were determined by incubating duplicate 
wells for 1 h at 37°C with 100 µL/well of individual serum 2 fold serially diluted from 1:100 
to 1:25,600 (v/v) in SMPBST. Wells were washed and bound murine IgG was detected by 
incubating wells for 1 h at 37°C with 100 µL/well alkaline phosphatase (AP) conjugated 
anti-mouse IgG (H+L) (Promega, Madison, Wisc.) diluted 1:5000 (v/v) in SMPBST. 
Individual wells were washed and developed for 30 min at RT with 100 µL/well AP 
substrate, 0.5 mg/mL p-nitrophenyl phosphate-containing buffer (Sigma Aldrich). The 
optical density (OD) was determined spectrophotometrically at 405 nm using an 
UltraMicroplate Reader, Model ELx800 (Bio-Tek Instruments, Inc., Winooski, Vt.).
Splenocyte Fusion and Hybridoma Screening
Mice were euthanized by CO2 asphyxiation 3 days following the final booster immunization 
with 25 µg 4,4′ -MDIKLH in sterile PBS. Hybridomas were produced according to standard 
polyethylene glycol-based cell fusion techniques using SP2/0-AG14 myeloma cells (ATCC# 
CRL-1581) as previously described.(17)
The supernatant fluid from confluent hybridomas was tested using the previously described 
indirect serum screening ELISA. Hybridomas that were confirmed by indirect ELISA to 
produce 4,4′-MDI specific mAb were selected and grown in bulk and then transferred to a 
96-well tissue culture plate and cloned twice by limiting dilution. Single positive clones 
were rescreened using the indirect ELISA, selected, grown in bulk, and purified according to 
the method of Kent.(19) Purified mAb was utilized in characterization studies. Hybridoma 
cell lines of individual clones were frozen in 10% dimethyl sulfoxide (DMSO, Sigma 
Aldrich) and 10% fetal calf serum, stored at −80°C for 2 weeks, and then transferred to a 
NIOSH liquid nitrogen facility for long-term storage.
Monoclonal Antibody Isotyping and Quantification
An indirect ELISA was used to determine the isotype and quantity of purified mAb. Briefly, 
96-well Nunc Immuno MaxiSorpmicroplates (Thermo Fisher Scientific) were coated with 
either 1 µg/mL AffiniPure goat anti-mouse IgG Fc subclass 1, 2a, 2b, or 3 (Jackson 
ImmunoResearch Laboratories Inc., West Grove, Pa.) in CCB and incubated overnight at 
RT. For murine IgM, wells were coated with 1 µg/mL AffiniPure goat anti-mouse IgM, µ 
chain specific polyclonal antibody in CCB, and incubated overnight at RT. Wells were 
washed with PBST and blocked for 1 h at RT with 200 µL SMPBST. Standard curves for 
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each isotype (IgG1κ, IgG2aκ, IgG2bκ, IgG3λ, and IgMκ; Sigma Aldrich) were prepared in 
duplicate and ranged from 100–0.6 ng/mL. Duplicate wells containing 100 µL/well purified 
mAb (1 µg /mL) were twofold serially diluted from 1:250 to 1:128,000 (v/v) in SMPBST 
and incubated for 1 h at 37°C. Isotype-specific mAbs were included as isotype-specific 
positive controls. Wells were washed and bound murine IgG isotype mAbs were detected by 
incubating wells with 100 µL/well AP conjugated anti-mouse IgG (H+L) (Promega, 
Madison, Wisc.) diluted 1:5000 (v/v) in SMPBST for 1 h at 37°C. For IgM isotype 
detection, wells were incubated for 1 h at 37°C with 100 µL/well biotin-SP-conjugated 
AffiniPure goat anti-mouse IgG + IgM (H+L) (Jackson ImmunoResearch Laboratories Inc.) 
diluted 1:5000 (v/v) in SMPBST. IgM isotype wells were washed and incubated for 1 h at 
37°C with 100 µL/well AP conjugated streptavidin (Jackson ImmunoResearch Laboratories 
Inc.) diluted 1:5000 (v/v) in SMPBST. Following secondary antibody incubations, 
individual wells of all isotype-specific plates were washed and developed for 30 min at RT 
with 100 µL/well AP substrate, 0.5 mg/mL p-nitrophenyl phosphate-containing buffer 
(Sigma Aldrich). The optical density (OD) was determined spectrophotometrically as 
previously described.
Western Blot Analysis of Murine IgM
The murine IgM mAb was separated by SDS-PAGE on a 12% polyacrylamide gel at 100 V 
and transferred to a 0.2 µm nitrocellulose membrane (BioRad, Hercules, Calif.) overnight at 
16 V as previously described.(20) The membrane was washed three times with tris buffered 
saline (TBS, Sigma Aldrich) containing 0.05% Tween 20 (TBST, Fisher Scientific) and then 
blocked with 3% bovine serum albumin (BSA) in TBST (blocking solution) for 1 h at RT. 
Confirmation of IgM pentameric structure was determined by incubating membrane lanes 1 
and 2 for 1 h at RT with rabbit anti-human IgM J-chain specific antibody (InvivoGen, San 
Diego, Calif.), a cross-reactive murine J-chain antibody, diluted 1:1000 (v/v) in blocking 
solution. Lanes 1 and 2 were washed followed by a 1 h incubation at RT with AP-
conjugated goat anti-rabbit IgG-Fc (Promega) diluted 1:5000 (v/v) in blocking solution. In 
contrast, Lanes 3 and 4 were incubated for 1 h with AP-conjugated rabbit anti-mouse IgM µ 
chain specific antibody (Mabtech, Cincinnati, Ohio) and lanes 5 and 6 were incubated for 1 
h at RT with AP-conjugated goat anti-mouse IgM (H+L) (Calbiochem, Billerica, Mass.), 
diluted 1:5000 (v/v) in blocking solution. Following secondary antibody incubation, the 
membrane was washed and immunoreactive proteins were visualized following 30 min 
incubation with One-Step nitroblue tetrazolium and bromocholor-indolyl phosphate (NBT/
BCIP) substrate (Promega).
Proteomic Identification of Murine IgM mAb
Murine IgM-specific bands identified in the western blot analysis were excised from 
imperial stained SDS-PAGE gels prepared in parallel. Excised spots were digested with 
porcine trypsin (Sigma Aldrich) and analyzed using a nanoACQUITY UPLC coupled to a 
SYNAPT quadrupole time-of-flight mass spectrometer (Waters, Milford, Mass.) according 
to previously published methods.(20–22)
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Conjugation of dNCOs to Human Serum Albumin
Diisocyanates, including 4,4′-MDI, 2,4-toluene diisocyanate (2,4-TDI), 2,6-toluene 
diisocyanate (2,6-TDI), and 1,6-hexamethylene diisocyanate (1,6-HDI), and the electrophilic 
chemicals (EC) 4,4′-methylene bis(phenyl isothiocyanate) (4, 4’-MDIT) and 4,4′-
biphenyldicarboxaldehyde (4,4′-BPCA), were prepared in 0.01 M PBS (pH 7.4) and 
conjugated to 0.5 mg/mL HSA (3.0 × 10−4 M). Stock solutions were prepared by dissolving 
each dNCO and EC (3.0 × 10−2 M) in dry acetone immediately prior to conjugation. dNCO 
and EC stock solutions were further diluted in acetone to 1.5 × 10−2 M, 7.5 × 10−3 M, 3.75 × 
10−3 M, 7.5 × 10−4 M, and 7.5 × 10−5 M and then conjugated to 0.5 mg/mL HSA for the 
preparation of 40:1, 20:1, 10:1, 5:1, 1:1, and 0.1:1 molar ratio conjugations, respectively. 
dNCO and EC-HSA conjugations were prepared by adding 50 µl of each dNCO or EC 
solution to 5mL HSA solution drop wise while vortexing. The conjugates were then 
incubated on a vortex for 1 h at RT. After incubation, conjugates were dialyzed using 12,144 
MWCO dialysis membrane (Sigma Aldrich) to remove residual polymerized dNCO, EC, or 
other amines generated following dNCO hydrolysis. Samples were stored at 4°C throughout 
the duration of experiments. All chemicals used in the conjugation of dNCO or EC to HSA 
were obtained from Sigma-Aldrich.
dNCO-HSA Murine IgM Sandwich ELISA
Murine IgM mAb 15D4 reactivity to dNCO/EC-HSA conjugates was analyzed by sandwich 
ELISA. Briefly, Corning high protein binding 96-well plates (Corning, Corning, N.Y.) were 
coated with 4 µg/mL AffiniPure goat anti-mouse IgM, µ chain specific antibody (Jackson 
ImmunoResearch Laboratories Inc.) in 0.1Msodium carbonate buffer, pH 9.6 overnight at 
4°C. Following overnight incubation, the wells were washed three times with PBST and 
incubated on a shaker for 1 h at RT with 2 µg/mL mAb 15D4. The wells were blocked with 
200 µL/well SMPBST for 1 h at 37°C. Duplicate wells containing 100 µg/mL dNCO-HSA 
or EC-HSA conjugates at each molar ratio were twofold serially diluted to 98 ng/mL in 
SMPBST and incubated for 1 h at 37°C. Wells were washed and incubated for 1h at 37°C 
with biotin-conjugated affinity purified rabbit anti-HSA antibody (Rockland, Gilbertsville, 
Pa.) diluted 1:5000 (v/v) in SMPBST. Following incubation, the wells were washed and 
incubated for 1 h at 37°C with AP-conjugated streptavidin (Jackson ImmunoResearch 
Laboratories Inc.) diluted 1:5000 (v/v) in SMPBST. Binding of murine mAb 15D4 to each 
dNCO or EC-HSA conjugate was quantified using 0.5 mg/mL p-nitrophenyl phosphate 
(Sigma Aldrich) in AP substrate. The optical density was determined spectrophotometrically 
as previously described. The limit of detection (LOD) and limit of quantification (LOQ) for 
each dNCO were defined as 3 and 10 times the standard deviation of 24 replicate HSA (0.5 
µg/mL) control wells.
Detection of dNCO-HSA Conjugates in Supplemented Deidentified Human Serum
Nine de-identified human sera were supplemented with each dNCO-HSA conjugate in 
proof-of-concept experiments to determine the applications of the sandwich ELISA for the 
serological detection of dNCO for occupational cohort studies. Briefly, plates were prepared 
as described in the sandwich ELISA. After blocking, the plates were then incubated with de-
identified human serum diluted 1:20 in SMPBST. Duplicate wells were then supplemented 
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with 100 µg/mL 40:1 dNCO-HSA conjugates and twofold serially diluted to 98 ng/mL in 
SMPBST and incubated for 1 h at 37°C. The remainder of the procedure was performed as 
described previously.
RESULTS
Hybridoma Screening and Antibody Characterization
Figure 1A outlines the methodology used for the production of MDI-specific mAbs. The 
splenocyte-myeloma cell fusion resulted in one hybridoma that secreted a 4,4′-MDI specific 
mAb. Isotyping experiments revealed the hybridoma to produce a murine IgM isotype mAb 
(mAb 15D4). The isotype of mAb 15D4 was further confirmed in nanoUPLC-MS/MS and 
Western blot analysis (Figure 2). Figure 2 shows an immunoblot of IgM heavy (78 kDa) and 
light (25 kDa) chains as well as a truncated heavy chain localized at ~55 kDa separated on a 
denaturing gel. Constant and variable regions were identified in both the 78 kDa heavy chain 
and the 25 kDa light chain in the nanoUPLC-MS/MS proteomic analysis. Proteomic analysis 
of the ~55 kDa truncated heavy chain resulted in the identification of a constant region but 
not a variable region (Figure 2). A truncated murine IgM heavy chain has been previously 
reported for an IgM producing hybridoma.(23) mAb 15D4 does not appear to be a pentamer 
as a murine Jchain (~15kD) could not be identified in either the proteomic or Western blot 
analysis (Figure 2). Native PAGE analysis of mAb 15D4 suggested that the mAb was 
multimeric with up to six subunits (data not shown).
Quantification of 4,4′-MDI-HSA Conjugates
A sandwich ELISA was developed to determine the reactivity of mAb 15D4 to 4,4′-MDI-
HSA conjugates (Figure 1B). 4,4′-MDI molar ratios including 40:1, 20:1, 10:1, 5:1, 1:1, and 
0.1:1 were conjugated to HSA and tested in the sandwich ELISA. mAb 15D4 reacted with 
the 40:1, 20:1, 10:1, and 5:1 4,4′-MDI-HSA conjugates in a concentration-dependent 
manner (Figure 3A). At a 20:1 4,4′-MDI-HSA molar ratio, all HSA was haptenated by at 
least 1 MDI molecule. No mAb 15D4 reactivity was observed in samples at either the 1:1 or 
0.1:1 4,4′-MDI-HSA conjugation ratios (data not shown). The LOQ for the 40:1 4,4′-MDI-
HSA sandwich ELISA assays was 567.2 ng/mL (8.67 pmol/mL) (Table I).
mAb 15D4 Binding to Other dNCOs
mAb 15D4 binding specificity was also tested against other occupationally relevant dNCO-
HSA conjugates. Figure 3 shows mAb 15D4 reactivity to the aromatic dNCO-HSA adducts, 
2,4-TDI-HSA (Figure 3B), and 2,6-TDI-HSA (Figure 3C) as well as the aliphatic dNCO, 
1,6-HDI-HSA (Figure 3D). mAb 15D4 reacted to all 3 additional dNCOs (Figure 3B–D, 
Table I). Compared to 4,4′-MDI-HSA, mAb 15D4 reactivity was over 50% greater for 2,4-
TDI-HSA, 2,6-TDI-HSA, and 1,6-HDI-HSA at 25 µg/mL 40:1 dNCO-HSA (Table I). A 
decrease in reactivity at a 20:1 molar ratio for both TDI-HSA adducts as well as 1,6-HDI-
HSA was also observed (Figure 3B and 3C). The LOQ for the dNCO-HSA sandwich ELISA 
assays for 40:1 2,4-TDI-HSA, 2,6-TDI-HSA, and 1,6-HDIHSA were 172.7, 184.2, and 
403.5 ng/mL (2.60, 2.77, and 6.07 pmol/mL), respectively (Table I).
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mAb 15D4 Reactivity to Other Electrophilic Chemicals
Due to the structural similarities with 4,4′-MDI-HSA, 4,4′-MDIT (aromatic 
diisothiocyanate), and 4,4′-BPCA (aromatic aldehyde) were selected to further characterize 
the binding determinants of mAb 15D4. 4,4′-MDIT haptenated HSA differed from 4,4′-
MDI-HSA in that the urea linkage is changed to a thiourea (substituting a carbonyl; C=O for 
a thioketone; C=S) (Table I). In contrast, the aromatic ring of the 4,4′-BPCA hapten is 
linked to the HSA by an imine group, shortening the distance between HSA and the 
aromatic ring of the adduct through the removal of the carbonyl moiety (C=O). mAb 15D4 
reactivity was only 15.1% for 4,4′-MDIT-HSA and 4.4% 4,4′-BPCA-HSA compared to 4,4′-
MDI-HSA (Figure 4, Table I). These data further suggest that the major binding determinant 
of mAb 15D4 is the dNCO urea linkage onto the protein.
Detection of dNCO-HSA Supplemented Human Serum
The utility of the sandwich ELISA for the detection of dNCO protein adducts was examined 
by supplementing deidentified human serum (n−9) with 2 fold serial dilutions of 100 µg/mL 
40:1 dNCOs-HSA. In preliminary experiments, dilutions ranging from neat, 1:5, 1:10, and 
1:20 were empirically tested to determine the optimal dilution for the sandwich ELISA. 
Non-specific binding of human serum proteins to mAb 15D4 was observed in all controls 
for each tested dilution. Background interference was reduced at 1:20 and this dilution was 
selected for the experiments (data not shown). Figure 5 shows the reactivity of mAb 15D4 
dNCO-HSA to each serum sample. At 25 µg/mL, mAb binding to adducted HSA in these 
assays was 30.5%, 57.6%, 46.4%, and 56.1% less compared to that observed in the initial 
sandwich ELISA results for 4,4′-MDI-HSA, 2,4-TDI-HSA, 2,6-TDIHSA, and 1,6-HDI-
HSA, respectively. The LOD for the immunoassays ranged from <0.1 to 11.5 µg/mL in non-
atopic (tIgE <100 kU/L) sera (n = 4) and 1.9 to 52.5 µg/mL in atopic (tIgE >100 kU/L) sera 
(n = 5) compared to the LOD in the initial sandwich ELISA which was <0.1 µg/mL. These 
data demonstrate that serum proteins may interfere with the binding of the mAb 15D4 to 
dNCO adducted HSA in this immunoassay.
DISCUSSION
Methods to assess dNCO occupational exposure have included the detection of dNCO 
specific serum immunoglobulins or signature dNCO biomarkers using chromatographic 
methods. The quantification of dNCO-derived (di-) amines from hydrolyzed clinical 
samples, such as urine, is a common approach for biomonitoring worker exposures.(24,25) 
However, toxicological kinetic studies of workers who received an inhaled dNCO challenge 
have shown that the excretion half-life of dNCOs ranges between 2.5 and 24 hours.(25) As a 
result, the detection of isocyanate metabolites in hydrolyzed urine samples at the end of an 
8-hour work shift may not be an accurate assessment of worker exposure.(25) In contrast, 
animal studies have shown that [14C]-dNCO (presumably adducted to proteins or other 
biomolecules) is available systemically following exposure.(24) Greatest amounts of [14C]-
dNCO were localized in the respiratory and gastrointestinal tracts as well as the blood.(24) 
Kennedy and Brown(26) have shown that dNCO forms adducts with blood and plasma 
proteins, in particular hemoglobin and HSA.(27–29) As a result of the longer half-lives of 
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dNCO-protein adducts, researchers have focused on these detectable biomarkers for 
assessing dNCO occupational exposure.(29)
Immunoassays for the detection of dNCO-protein adducts is an important development to 
quantify occupationally relevant dNCOs. In the past 3 years, significant advances in the 
production of dNCO-protein adduct reactive antibodies have been reported. We have 
reported 29 TDI-HSA specific IgG isotype mAbs(17) as well as 10 TDI-protein adduct 
specific IgM mAbs.(16) Recently, Wisnewski and Liu have produced 6 MDI-protein adduct 
specific IgG1 isotype mAbs.(18) pAbs have also been produced for 1,6-HDI(15,30) and 
TDI.(31) Although the specificity and application of these antibodies in immunoassays have 
been established, their utility in detecting dNCO-protein adducts in human serum or other 
clinical samples has not been fully evaluated. The utility of these dNCO-specific antibodies 
for biomonitoring occupational dNCO exposure is further confounded by worker exposures 
to combinations of dNCOs. In autobody painting operations, HDI and TDI, or more 
commonly, HDI and IPDI, may be used concurrently.(25,32,33) In this study, we produced an 
IgM mAb with broad specificity to occupationally relevant dNCO-HSA adducts, including 
1,6-HDI, 2,4-TDI, 2,6-TDI, and 4,4′-MDI.
In preliminary characterization studies, a sandwich ELISA was developed andmAb15D4was 
shown to broadly react with each dNCO adducted HSA. The LOQ of the sandwich ELISA 
ranged between 173 ng/mL (2.60 pmol/mL) for 40:1 2,4-TDIHSA to 567 ng/mL (8.67 
pmol/mL) for 40:1 4,4′-MDI-HSA. Reactivity with other occupationally relevant dNCOs, 
such as IPDI and 1,5-naphthalene diisocyanate (NDI) was not determined. In addition, 
occupational exposure to dNCO oligomers has been previously reported, however, higher 
oligomers of dNCO species, such as the prominent MDI trimer, were not evaluated in this 
study. The mAb 15D4 assay results were comparable to the 1,6 HDI-HSA pAb sandwich 
ELISA reported by Lemus et al.(15) Although the mAb 15D4 sandwich ELISA was 
sufficient to demonstrate reactivity to dNCO-HSA adducts, its application in detecting 
adducts in human serum required further evaluation.
In experiments using de-identified human serum supplemented with dNCOs, 4,4′-MDI, 2,4-
TDI, 2,6-TDI, and 1,6-HDI adducted HSA were detected in a concentration-dependent 
manner. However, the detectable limit of the immunoassay appeared to be confounded by 
non-specific human serum protein binding to solid phase IgM mAb 15D4 as reported values 
were outside the range of dNCO plasma concentrations reported in workers (8-hour 
shift).(28,34) Previous studies have reported non-specific binding of HSA and dNCO-HSA 
conjugates with serum immunoglobulins including IgE(35) and IgG.(36) Nonspecific binding 
of murine IgM to other human proteins and lipid antigens has also been reported.(37,38) Glee 
and colleagues have also identified a unique set of peptide ligands that bind murine, rabbit, 
and human pentameric and monomeric IgM via proposed determinants within the heavy 
chain constant regions.(38) Certain motifs including WIS/PS/QXDW and a C-terminal 
aspartate-tryptophan residue set were commonly associated with peptide sequences that 
bound murine IgM.(38) To overcome non-specific binding interactions, human serum was 
diluted 1:20 and also pre-incubated with 50 µg/mL of control murine IgM. Human serum 
dilutions improved assay performance; however, inhibition with a control murine IgM mAb 
did not improve non-specific binding interactions (data not shown). Future studies are 
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required to examine the inhibitory role of preincubating IgM mAb 15D4 with peptide 
ligands that bind murine IgM antibodies. Identification of a suitable peptide ligand may 
improve the overall utility of the sandwich assay for the serological detection of dNCO-
protein adducts.
The reactivity of mAb 15D4 to occupationally relevant dNCOs was determined in mAb 
binding studies. mAb reactivity to 2,4-TDI-HSA, 2,6-TDI-HSA, and 1,6-HDI was greatest, 
whereas reduced binding to 4,4′-MDI was observed in both sandwich ELISAs. 
Characterization of the binding determinants of mAb 15D4 was evaluated by testing other 
electrophilic chemical HSA conjugates with similar structures to occupationally relevant 
dNCOs. In this series of experiments, 4,4′-MDIT (aromatic diisothiocyanate) and 4,4′-
BPCA (aromatic aldehyde) were selected because of the structural similarities with 4,4′-
MDI-HSA.
However, 4,4′-MDIT-HSA differs from 4,4′-MDI-HSA in that the urea linkage is changed 
to a thiourea (substituting a carbonyl; C−O for a thioketone; C−S). In contrast, the aromatic 
ring of the 4,4′-BPCA-HSA is linked to HSA by an imine group, resulting in the removal of 
the carbonyl moiety (C−O) and shortening the distance between the hapten aromatic ring 
and the protein. mAb 15D4 showed little to no reactivity with either 4,4′-BPCA-HSA or 
4,4′-MDIT-HSA. These data suggest that the major mAb binding determinant revolves 
around the urea linkage between the dNCO and the protein. These findings are of additional 
importance as isothiocyanates are commonly found in the environment and cruciferous 
vegetables.(36)
Although mAb 15D4 reactivity to dNCO-HSA adducts was the focus of the current study, 
the conjugation of dNCOs to other proteins associated with respiratory and dermal 
exposures has also been reported.(4) dNCOs may conjugate to an assortment of host 
bronchial epithelial proteins following respiratory exposures.(31,39) In addition to albumin, 
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase, actin, ciliary tubulin, keratin 18, and 
glucose-regulated proteins have been identified in human/animal bronchalveolar lavage and 
biopsy samples.(30,40) In contrast, keratin was one of the major proteins associated with 1,6-
HDI adduction following dermal exposures.(30)
In the present study, mAb 15D4 reactivity to other protein dNCO-conjugates was not 
evaluated; however, reactivity to 40:1 4,4′-MDI-keratin was identified in preliminary mAb 
screening studies (data not shown). These data demonstrate the potential utility of mAb 
15D4 for the enrichment of other dNCO protein adducts in human or animal studies of 
dNCO respiratory or dermal exposure. Furthermore, Mhike and colleagues have recently 
shown the potential utility of mAb 15D4 for the characterization and standardization of 
dNCO protein adducts used to detect specific antibody in exposed worker sera.(41)
Preliminary studies by Luna and colleagues have recently demonstrated application 
ofmAb15D4 to concentrate and partially purify MDI-HSA to decrease the LOD in a liquid 
chromatography tandem mass spectrometry method (LC/MS/MS) to quantify 4,4′-MDI 
signature peptide biomarkers.(42) Using this LC/MS/MS approach, the MDI adducted 
K(MDA)VPQVS TPTLVEVSR peptide was the most frequently quantified adduct and 
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accounted for 10.3% of total MDI adducted HSA (0.1 mg/mL HSA digested). The results of 
this preliminary analysis were comparable in sensitivity to Sabbioni’s method for detection 
of MDI-lysine amino acids adducts following pronase digestion;(43) however, the detection 
of dNCO-HSA conjugates in workers exposed to dNCO requires further validation and is 
the focus of future research efforts.
CONCLUSION
Amurine IgM mAb has been produced and characterization studies demonstrated broad 
reactivity to dNCOs that cause occupational allergic sensitization and OA. The specificity of 
the antibody for both aromatic and aliphatic dNCOs, but not isothiocyanates, suggests utility 
of the mAb for biomonitoring in mixed dNCO occupational environments, although 
reactivity to IPDI, a commonly used dNCO in the autobody industry, was not tested. This 
mAb may also have utility in the enrichment of dNCO-protein adducts in LC/MS/MS-based 
approaches to assess signature peptide biomarkers following worker exposure to 
occupational dNCOs.
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Schematic of the experimental design: (A) Flow diagram illustrating the methods used to 
produce the dNCO-specific IgM mAb 15D4; (B) Representation of an ELISA plate well 
from the murine IgM sandwich ELISA used to detect dNCO adducted has. (color figure 
available online)
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Western blot analysis of murine IgM mAb 15D4. Molecular weight (MW) markers: Bio-Rad 
Precision Plus Protein Standards, Lanes 1–2: mAb 15D4 probed with rabbit anti-human IgM 
J-chain specific antibody; Lanes 3–4: mAb 15D4 probed with AP-conjugated rabbit anti-
mouse IgM µ chain specific antibody; Lanes 5–6: mAb 15D4 probed with AP-conjugated 
goat antimouse IgM (H+L). Murine IgM mAb bands were then excised from corresponding 
Imperial protein stained SDS-PAGE gels and identified using mass spectrometry. (a) Mass 
spectrometric protein characterization of mAb 15D4 (UniProtKB/Swiss-Prot accession 
Lemons et al. Page 15













number) include (A) Ig mu chain C region Mus musculus (P01872) and Ig heavy chain V 
region Mus musculus (P06330), (B) Ig mu chain C region Mus musculus (P01872), and (C) 
Ig kappa chain C region Mus musculus (P01837), Ig kappa chain V VI region Mus musculus 
(P04942), Ig kappa chain C region Mus musculus (P01837), and Ig kappa chain V VI region 
Mus musculus (P04941). (color figure available online)
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Binding of IgM mAb 15D4 to other occupationally relevant diisocyanates. (A) ELISA 
results of IgM mAb 15D4 binding different molar ratios of 4,4′-MDI-HSA, (B) 2,4-TDI-
HSA, (C) 2,6-TDI-HSA, and (D) 1,6-HDI-HSA. The results of panel A represent the mean 
OD405 values corrected for HSA background of duplicate ELISA assays containing 2 well 
replicates. The results of panels B–D represent the mean OD405 values corrected for HSA 
background of 2 ELISA well repeats. Background controls using 0.5 µg/mL HSA were 
examined in parallel. (color figure available online)
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Binding of IgM mAb 15D4 to other isocyanate-like compounds. ELISA results of IgM mAb 
15D4 binding 40:1 molar ratios of 4,4′-MDI-HSA, 2,4-TDI-HSA, 2,6-TDI-HSA, 1,6-HDI-
HSA, 4,4′-MDIT-HSA, and 4,4′-BPCA-HSA. The results represent the mean OD405 values 
corrected for HSA background of 2 ELISA well repeats. Background controls using 0.5 
µg/mL HSA were examined in parallel. (color figure available online)
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Binding of IgM mAb 15D4 to diisocyanate-HSA conjugates in deidentified human sera. 
ELISA results of IgM mAb 15D4 binding 40:1 molar ratios of 4,4′-MDI-HSA, 2,4-TDI-
HSA, 2,6-TDI-HSA, and 1,6-HDI-HSA in deidentified human sera diluted 1:20. The results 
represent the mean OD405 values corrected for 0.5 µg/mL HSA background of duplicate 
ELISA assays containing 2 well replicates. Background controls using deidentified human 
sera diluted 1:20 were examined in parallel. (color figure available online)
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4,4′methylene diphenyl diisocyanate 4,4′MDI-HSA 1.100±0.013 — 567.2
2,4-toluene diisocyanate 2,4-TDI-HSA 1.85 ± 0.057 168.8% 172.7
2,6-toluene diisocyanate 2,6-TDI-HSA 1.724 ± 0.079 156.7% 184.2
1,6-hexamethylene diisocyanate 1,6-HDI-HSA 1.666 ± 0.019 151.5% 403.5
4,4′methylenebis(phenyl isothiocyanate) 4,4′MDIT-HSA 0.167 ± 0.087 15.1% NA
4,4′biphenyldicarboxaldehyde 4,4′BPCA-HSA 0.049 ± 0.043 4.4% NA
A
The results represent the mean OD405 values of each 40:1 hapten-HSA corrected for 0.5 µg/mL HSA background of 2 ELISA well repeats. 
Background controls using 0.5 µg/ml HSA were examined in parallel. Limit of quantification was determined by calculating the concentration of 
dNCO-HSA that corresponded to 10x the standard deviation of sandwich ELISA 0.5 µg/mL HSA control absorbance values. Chemical structures 
and hapten-protein interactions are illustrated along with each chemical hapten abbreviation.
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